 |
NeurologyLive® Mind Moments®Author: NeurologyLive Language: en Genres: Education, Health & Fitness, Medicine Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
178: Evolving Approaches to Epilepsy Clinical Trial Design
Episode 178
Friday, 30 October, 2026
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, M. Scott Perry, MD, head of neurosciences at Cook Children's Medical Center, discussed how epilepsy trial design is evolving, including basket trials that group related conditions, approaches to reduce placebo exposure, and greater inclusion of children under the age of 2 years. He also highlighted a growing focus on outcomes beyond seizure frequency, such as cognition, development, and behavior, particularly in developmental epileptic encephalopathies. During the conversation, Perry also described electroencephalography (EEG) measures as an emerging exploratory biomarker and sees potential for genetic, serum, and imaging markers to help identify patients most likely to benefit from treatment. Looking ahead, Perry noted that he envisions more targeted trials that may be smaller and shorter, with less reliance on placebo as researchers better understand disease biology and natural history. Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy focus page.Episode Breakdown: 1:10 - Evolution of epilepsy trial design 3:44 - Outcomes beyond seizure frequency 5:38 - Biomarkers in current trials 6:17 - Neurology News Minute 8:48 - Biomarkers and epilepsy heterogeneity 10:35 - Genetic screening in epilepsy trials 12:38 - Vision for future clinical trials The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis FDA Grants Fast Track to AV-1959R for Alzheimer Prevention FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
